Pravastatin
A statin medication used to lower elevated cholesterol and triglyceride levels in the blood, reducing the risk of heart attacks, strokes, and the need for heart procedures. It is generally well tolerated and has fewer drug interactions than some other statins.
Masse moléculaire
424,5280 g/mol
LogP
1,60
TPSA
124,00 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Classes de médicaments
Mécanisme d'action
Competitive inhibitor of HMG-CoA reductase.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitive inhibitor of HMG-CoA reductase.
Structure 2D
Cite this structure
Embed this structure
SMILES
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21
InChI
InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
Molecular Formula
C23H36O7
HBD / HBA
4 / 7
Liaisons Rotatives
11
Atomes Lourds
30
Fluconazole has minimal effect on pravastatin exposure because pravastatin is not significantly metabolised by CYP enzymes; the interaction is pharmacokinetically unimportant in most patients.
Concurrent use of colchicine and pravastatin carries a small theoretical risk of myopathy, as both drugs individually can cause muscle toxicity, though the combination is better tolerated than colchicine with …
Cyclosporine inhibits OATP1B1/1B3 hepatic transporters and P-glycoprotein, substantially increasing pravastatin plasma concentrations and raising the risk of myopathy and rhabdomyolysis.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A statin medication used to lower elevated cholesterol and triglyceride levels in the blood, reducing the risk of heart attacks, strokes, and the need for heart procedures. It is generally well tolerated and has fewer drug interactions than some other statins.
Competitive inhibitor of HMG-CoA reductase.
Key pharmacokinetic parameters for Pravastatin: Half-life: 1.8 hours.
Yes, Pravastatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1144. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 54687. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="pravastatin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/pravastatin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/pravastatin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/pravastatin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="pravastatin"></drugfyi-drug>